A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Part of paid clinical trials in Los Angeles, California.

Sponsor
AstraZeneca
Study ID
NCT07571746
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Primary Membranous Nephropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Surovatamig — DRUG
    Participants will receive Surovatamig subcutaneously

Study Details

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.

Key Dates

Start date
Mar 28, 2026
Status verified
Apr 2026
Primary completion
Apr 24, 2028
Completion
Oct 15, 2029

Study Design

Enrollment
43 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Surovatamig Arm
    Participants will receive Surovatamig

Primary Outcome Measure

Number of participants with adverse events. [ Time Frame: Through study completion, an average of 2 years ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Research SiteLos AngelesCalifornia90095-
Research SiteIowa CityIowa52242-
Research SiteBethesdaMaryland20889-
Research SiteNew YorkNew York10016-
Research SiteHoustonTexas77027-
Research SiteHoustonTexas77030-

Find similar trials in Los Angeles, CA

By research site
Research Site· Los Angeles, CAResearch Site· Iowa City, IAResearch Site· Bethesda, MDResearch Site· New York, NYResearch Site· Houston, TX

Related Studies